Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Dobrosloveni – page 5

328 clinical trials in Dobrosloveni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Dobrosloveni at a glance
328
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

328 trials in Dobrosloveni

Open in trial search

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:BMN 333
  • Sponsor:Biomarin Pharmaceutical Inc.

A study to evaluate the effectiveness and safety of efaglomograstim alfa in patients with low blood platelet counts caused by chemotherapy

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Rafutrombopag ethanolamine
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Asthma

Recruiting

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Dobrosloveni

What the registry says about research in the country

01 Cardiovascular Disease Trials

Clinical research in Dobrosloveni concentrates on Cardiovascular Diseases, with a primary focus on Atrial Fibrillation. The studies aim to evaluate innovative treatments that could reduce stroke, systemic embolism, and major bleeding risks.

  • Evaluation of the novel anticoagulant REGN7508 compared with standard therapy
  • Assessment of combined agents REGN7508 and REGN9933 versus placebo
  • Investigation of major bleeding outcomes in atrial fibrillation patients
  • Exploration of options for individuals unsuitable for oral anticoagulation

The single research site, supported by one investigator, is actively recruiting participants to generate safer and more effective strategies for preventing stroke and systemic embolism in the local community.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.